THG

THG shares fell about 13.4% to 27.44 pence after the company published interim results for H1 2026. Revenue rose on a constant-currency basis to £828.7m (+7.2%) and adjusted EBITDA doubled to £42.8m, but management’s warning that the abolition of the EU de-minimis rule and the introduction of a flat €3 fee per parcel will dampen Q3 revenue growth to around 2% unsettled investors. THG Beauty is expected to be particularly affected; additionally weighed down were an outstanding VAT claim in Nutrition of £60m and net debt of £329.7m. Management expects a recovery with 6–7% growth in Q4 and confirms the full-year guidance, but short-term execution and balance-sheet risks pushed the stock to a 52-week low. » More on de.investing.com

THG increased revenue in H1 2026 by 7.2% to £828.7m and doubled adjusted EBITDA to £42.8m. Myprotein sold 58.5 million units (+57%) and management is targeting positive free cash flow of £25–35m for 2026 as well as a reduction in leverage by the end of 2027. Despite improved profitability, the share fell about 6.8% to $29.53 as investors await sustained evidence of growth amid uncertainties over asset disposals and supply‑chain and customs concerns. THG highlights progress on restructuring and plans further growth in nutrition and beauty, including the use of AI in the beauty segment. » More on de.investing.com

THG reported a 2.3% revenue increase for the 2025 financial year to £1.72 billion and an operating profit of £8.1 million after a prior-year loss. Adjusted EBITDA was £76.6 million (4.5% of revenue); the second half beat analyst expectations by around 15%. The company reduced debt, extended credit facilities to 2029 and completed the demerger of THG Ingenuity. Free cash flow remained negative in 2025 at -£51.8 million; management expects positive free cash flow of £25–50 million in 2026 and confirms growth expectations for revenue and adjusted EBITDA. » More on de.investing.com